Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results
Vanda Pharmaceuticals reported Q3 2026 revenue of $69.8M, up 24% YoY, and operating expenses of $93.3M, down 18% QoQ. The company announced positive Phase III results for NEREUS™ in GLP-1-induced vomiting and expects to launch BYSANTI™ in Q4 2026. Quimilza™ BLA for GPP is under FDA review with a PDUFA date of December 12, 2026.
How this was made
The 30-second read
Why it matters
The combination of revenue growth and positive trial data provides a catalyst for short-term price appreciation.
Market read
New earnings and trial data create a fresh trading opportunity for VNDA.
What to watch
Cash burn remains high and upcoming launch costs could pressure margins.
Background
Press release from Vanda Pharmaceuticals detailing Q3 2026 financials and clinical milestones.
Ticker impact
First report of Vanda Pharmaceuticals' Q3 2026 results and positive Phase III data for NEREUS, plus upcoming launches and FDA review milestones.
likely upward pressure as investors price in higher sales and successful trial outcomes
Quarterly revenue up 24% YoY, operating expense decline, and Phase III success are material new information for a biotech stock.
Market effects
Positive biotech trial results may lift peer sentiment in the specialty pharma sector.
U.S. biotech market could see modest gains as investors rotate into growth pipelines.
Limited to biotech investors; no broad macro impact.
Counterpoint
If trial data fails to translate into FDA approval, the hype could reverse quickly.
Key entities
- companyVanda Pharmaceuticals Inc.
US-listed biotech company reporting Q3 2026 results.
